NCT05256719View on ClinicalTrials.gov

Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Health Volunteer
Interventions
BIOLOGICAL

Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.

BIOLOGICAL

Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.

BIOLOGICAL

Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.

BIOLOGICAL

Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.

BIOLOGICAL

Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.

BIOLOGICAL

Placebo-1mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg

BIOLOGICAL

Placebo-2.5mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg

BIOLOGICAL

Placebo-5mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg

BIOLOGICAL

Placebo-7.5mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg

BIOLOGICAL

Placebo-10mg/kg

Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Beijing VDJBio Co., LTD.

INDUSTRY